In many cases, the vaccine is not successfully designed because the candidate failed to elicit an appropriate immune response. Therefore, it is desirable to combine an immunomodulatory or adjuvant with an improved delivery vehicle to improve the quality of vaccine production. Creative Biolabs has experts in developing vaccine delivery vehicles, including nanoparticles, liposomes, micelles and immunostimulating complexes (ISCOM). Our vaccine delivery optimization strategy can provide you with the best advice and accelerate your vaccine development program.
Liposomes and their derivatives "liposome complexes" (liposomes/DNA complexes) are hollow spherical constructs of phospholipid bilayers, which can capture hydrophilic moieties in aqueous compartments, the hydrophobic part in lipid bilayers. As vaccine adjuvants, these systems exert immunomodulatory effects by virtue of their granular nature and their ability to bind to cell surface lipid receptors following complement activation.
Emulsions are heterogeneous liquid systems, which can be water-in-oil emulsions, oil-in-water emulsions, or more complex systems. The results of physicochemical characterization studies and in vitro release studies indicate that the emulsified formulation has uniform fine particles, good stability and reproducibility, thus is superior to vaccines prepared with conventional adjuvants.
Due to their size, polymeric nanoparticles are preferentially absorbed by mucosa-associated lymphoid tissues. Therefore, the use of nanoparticles for oral delivery of antigens is suitable. Nanocarrier types include metal oxide particles, polysaccharide-based spermines, alginate capsules, and synthetic biocompatible and biodegradable copolymers.
Micellars have been well studied as potential antigen carriers. A micelle is a self-aggregating cluster of amphiphilic surfactant molecules. Surfactants above the critical micelle concentration act directly on the micellar structure to avoid contact with incompatible external phases and can encapsulate lipophilic or hydrophilic cavities (reverse micelles) to promote antigenic capture and transport to the body.
For more details, please feel free to contact us for project quotations and more detailed information.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE